Technical Analysis for ACST - Acasti Pharma, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Hammer Candlestick | Bullish | 0.00% | |
| Lizard Bullish | Bullish Day Trade Setup | 0.00% | |
| Volume Surge | Other | 0.00% |
| Alert | Time |
|---|---|
| Gapped Down (Partial) | about 10 hours ago |
| Down 3% | about 10 hours ago |
| Fell Below Lower Bollinger Band | about 10 hours ago |
| Fell Below 50 DMA | about 10 hours ago |
| Down 2 % | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/09/2024
Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for abnormalities in blood lipids, and the treatment and prevention of cardiovascular disorders. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trial for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cardiovascular Disease Lipid Drug Products Metabolic Disorders Fatty Acids Triglyceride Hypertriglyceridemia Medical Food Onemia
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cardiovascular Disease Lipid Drug Products Metabolic Disorders Fatty Acids Triglyceride Hypertriglyceridemia Medical Food Onemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 3.834 |
| 52 Week Low | 1.72 |
| Average Volume | 14,477 |
| 200-Day Moving Average | 2.74 |
| 50-Day Moving Average | 2.92 |
| 20-Day Moving Average | 3.11 |
| 10-Day Moving Average | 3.11 |
| Average True Range | 0.20 |
| RSI (14) | 44.13 |
| ADX | 38.82 |
| +DI | 10.12 |
| -DI | 33.85 |
| Chandelier Exit (Long, 3 ATRs) | 2.71 |
| Chandelier Exit (Short, 3 ATRs) | 2.83 |
| Upper Bollinger Bands | 3.39 |
| Lower Bollinger Band | 2.83 |
| Percent B (%b) | 0.17 |
| BandWidth | 17.97 |
| MACD Line | 0.02 |
| MACD Signal Line | 0.06 |
| MACD Histogram | -0.039 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.09 | ||||
| Resistance 3 (R3) | 3.07 | 2.99 | 3.06 | ||
| Resistance 2 (R2) | 2.99 | 2.95 | 3.00 | 3.05 | |
| Resistance 1 (R1) | 2.96 | 2.93 | 2.98 | 2.98 | 3.04 |
| Pivot Point | 2.88 | 2.88 | 2.89 | 2.89 | 2.88 |
| Support 1 (S1) | 2.85 | 2.84 | 2.87 | 2.87 | 2.80 |
| Support 2 (S2) | 2.77 | 2.82 | 2.78 | 2.79 | |
| Support 3 (S3) | 2.74 | 2.77 | 2.78 | ||
| Support 4 (S4) | 2.76 |
